5 results about "Colicin" patented technology

The invention discloses a multi-omics non-invasive intestinal cancer risk assessment method based on pks + intestinal bacteria, cancer driver genes and methylated molecular clocks, which comprises the steps of excrement DNA sample extraction, primer design and screening, triple specificity verification, non-invasive detection and multi-omics quantitative scoring model, and detection of pks + escherichia coli in excrement. The pks + Escherichia coli can synthesize cytotoxin colicin, induce DNA double-chain breakage and chromosome instability in host cells, cause cell cycle arrest and finally cause cell death, key information can be provided for cancer prevention, diagnosis and precise treatment, and the application has the advantages that the application is wide in application range and high in practicability. In addition, deep understanding of the key cancer driver gene of the intestinal cancer is helpful for studying the occurrence and development mechanism of the intestinal cancer, a new therapeutic target can be provided for the intestinal cancer, new possibilities are provided for early discovery, risk assessment and monitoring of the intestinal cancer, the screening accuracy and sensitivity are further improved, and the screening method is suitable for popularization and application. And the method has the advantage of higher accuracy in risk assessment of intestinal cancer.

The application belongs to the field of biological medicine, and particularly relates to an information bacteriocin array against small cell lung cancer and application thereof. Amino acid sequences such as SEQ ID NO: 1-30 are provided. A drug against small cell lung cancer is also provided, which comprises a fusion protein obtained by connecting a channel domain of colicin with polypeptides with amino acid sequences such as SEQ ID NO: 1-30. Pharmacodynamics experiments prove that in each growth cycle, a mouse tumor-bearing model cannot escape the recognition and killing of the information bacteriocin array composed of thirty kinds of fusion proteins. Guinea pig model experiments prove that the continuous use of the information bacteriocin array for 30 days does not produce any toxic side effects in the animal model. The information bacteriocin array can be used as an effective drug for treating small cell lung cancer.

The application belongs to the field of biological medicine, and relates to an anti-tumor pheromone array and application thereof. A polypeptide composition is provided, which comprises forty-six polypeptides, and the amino acid sequences of the forty-six polypeptides are shown as SEQ ID NO:1-46. An anti-tumor drug is also provided, which comprises forty-six fusion proteins, and the forty-six fusion proteins are obtained by connecting the channel forming domain of colicin with the forty-six polypeptides with the amino acid sequences shown as SEQ ID NO:1-46. Experiments prove that the pheromone array composed of the forty-six fusion proteins shows extremely significant growth inhibition and killing effects on pancreatic cancer cells and liver cancer cell-derived tumor models, and does not have any toxic side effects.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.